Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease

Jacinto, Jomel Patrick; Patel, Milan; Goh, Justin; Yamamura, Kenneth

doi:10.1016/j.hrcr.2021.05.004

Cited by 15 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since Fitbit’s measurement of RHR is not the lowest value of heart rate, this raises the possibility that the heart rate during sleep may reach dangerously low values. It is important to be aware of this transient relative bradycardia phase, since certain medications used in the treatment of COVID-19 such as Remdesivir have been known to cause bradycardia ( Gupta et al, 2020 ; Jacinto et al, 2021 ; Sanchez-Codez et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Occurrence of Relative Bradycardia and Relative Tachycardia in Individuals Diagnosed With COVID-19

Natarajan

Heneghan

2022

Front. Physiol.

View full text Add to dashboard Cite

The COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become one of the worst global pandemics of the century. Wearable devices are well suited for continuously measuring heart rate. Here we show that the Resting Heart Rate is modified for several weeks following a COVID-19 infection. The Resting Heart Rate shows 3 phases: 1) elevated during symptom onset, with average peak increases relative to the baseline of 1.8% (3.4%) for females (males), 2) decrease thereafter, reaching a minimum on average ≈13 days after symptom onset, and 3) subsequent increase, reaching a second peak on average ≈28 days from symptom onset, before falling back to the baseline ≈112 days from symptom onset. All estimates vary with disease severity1.

show abstract

Section: Discussionmentioning

confidence: 99%

Occurrence of Relative Bradycardia and Relative Tachycardia in Individuals Diagnosed With COVID-19

Natarajan

Heneghan

2022

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…Since Fitbit’s measurement of RHR is not the lowest value of heart rate, this raises the possibility that the heart rate during sleep may reach dangerously low values. It is crucial to be aware of this transient relative bradycardia phase, since certain medications used in the treatment of COVID-19 such as Remdesivir have been known to cause bradycardia 40–42 . Interestingly, mild cases of COVID-19 are more likely to present with relative bradycardia.…”

Section: Discussionmentioning

confidence: 99%

Occurrence of relative bradycardia and relative tachycardia in individuals diagnosed with COVID-19

Natarajan

Heneghan

2022

Preprint

View full text Add to dashboard Cite

BackgroundThe COVID-19 disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become one of the worst global pandemics of the century causing tremendous human and economic suffering worldwide. While considered a respiratory disease, COVID-19 is known to cause cardiac complications. Wearable devices are well equipped to measure heart rate continuously and their popularity makes them valuable devices in the field of digital health. In this article, we use Fitbit devices to examine resting heart rate from individuals diagnosed with COVID-19 aMethodsThe Fitbit COVID-19 survey was conducted from May 2020 - June 2021. We collected resting heart rate data from 7,200 individuals (6,606 symptomatic, 594 asymptomatic) diagnosed with COVID-19 between March 2020 - December 2020, as well as from 463 individuals diagnosed with influenza between January 2020 - December 2020. Data from healthy individuals served as a control, in order to model the seasonal variation. We also computed heart rate variability and respiratory rate data for symptomatic COVID-19.FindingsResting Heart Rate is elevated during COVID-19 symptom onset, with average peak increases relative to the baseline of 1.8%±0.1% (3.4%±0.2%) for females (males), where the quoted numbers are mean and standard error of the mean. After the initial peak, the resting heart rate decreased and reached a minimum on average ≈ 13 days after symptom onset. The minimum value relative to the baseline is more negative for females (−1.75% ± 0.1%) compared to males (0.08% ± 0.2%). The resting heart rate then increased, reaching a second peak on average ≈ 28 days from symptom onset, before falling back to the baseline ≈ 112 days from symptom onset. All estimates vary with disease severity.InterpretationThe resting heart rate is modified for several months following a COVID-19 diagnosis. Interestingly, this effect is seen with seasonal influenza also, although the bradycardia minimum and the second tachycardia peak are often more pronounced in the case of symptomatic COVID-19. By computing resting heart rate daily, wearable devices can contribute to monitoring wellness during recovery from COVID-19, and seasonal influenza.FundingA.N., H.-W.S., and C.H. are supported by Fitbit Research, Google LLC.Research in ContextEvidence before this studyWe searched PubMed, Google, and Google Scholar for research articles published in English up to Oct 31, 2021, using common search terms such as “bradycardia and COVID-19”, “cardiac complications and COVID-19”, etc. Articles were also retrieved by searching through citations of known literature. It is known that COVID-19 can cause cardiac complications such as bradycardia and arrhythmias. Using data from commercially available wearable devices, it has been shown previously that the resting heart is elevated during symptom onset, then decreases reaching a minimum, before rising again to attain a second peak, before finally returning to the baseline.Added value of this studyWe present results from the largest (to our knowledge) dataset considered to-date, involving 7200 participants (6606 symptomatic and 594 asymptomatic) diagnosed with COVID-19. We also present results from 463 individuals diagnosed with influenza. Our large dataset allows us to perform more detailed examinations by age, disease severity, and sex. We also discuss the time evolution of heart rate variability and respiratory rate. The heart rate variability shows a similar time evolution as the resting heart rate but with opposite phase, while the respiratory rate decreases monotonously following the peak at symptom onset.Implications of all the available evidenceThe results presented in this work show that commercially available trackers and smart-watches can help in monitoring heart health in the weeks and months following a COVID-19 diagnosis. An estimate of the amplitude of the bradycardia dip may provide information valuable to critical care.

show abstract

“…Bradycardia and hypotension have been reported in adults but may have been related to concomitant use of other medications. 46 Contraindications to its use are hypersensitivity to remdesivir or any component of the formulation. Remdesivir is not recommended in children older than 28 days with estimated glomerular filtration rate <30 mL/min, and in full-term neonates with serum creatinine level 1 mg/dL or greater and should be used with caution in those with baseline alanine transaminase (ALT) levels more than 5 times the upper limit of normal.…”

Section: Severe Acute Covid-19 Complicationsmentioning

confidence: 99%